Project Grant R01CA288743
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$660K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award in the amount of $544,768.00 was provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) federal grant program. The award is supporting research at the University of New Mexico Health Sciences Center (UNM HSC) to investigate the mechanisms by which the MEK signaling pathway regulates human papillomavirus (HPV) oncogene expression, and how MEK inhibition can lead to tumor regression in an HPV disease model. The research aims to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $533,707 to conduct research on how the human papillomavirus (HPV) regulates the Hippo signaling pathway. The goal is to elucidate the mechanism by which the HPV E7 oncoprotein activates the YAP1 oncoprotein by degrading the PTPN14 protein, which normally promotes epithelial cell differentiation. The research...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to investigate viral and host cell factors that contribute to the development of juvenile-onset recurrent respiratory papillomatosis (JORRP), a rare but serious condition caused by low-risk HPV viruses. The $446,728 award, which began on July 5, 2024 and is scheduled to run through June 30, 2029, will enable researchers at Childrens Hospital Medical Center in Cincinnati, Ohio to...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program supports research on the role of ERBB2 signaling in human papillomavirus (HPV)-induced pathologies. The $148,280 award to the Children's Hospital Medical Center in Cincinnati, Ohio will utilize 3D organotypic epithelial rafts to spatially resolve ERBB2 expression, activation, and downstream signaling in HPV-positive and HPV-negative cells. The research aims to determine if ERBB2...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), is focused on understanding how human papillomavirus (HPV) disrupts DNA damage response signaling in HPV-positive head and neck squamous cell carcinoma (HNSCC). The $249,000 award aims to clarify the mechanisms by which HPV sensitizes cancer cells to the WEE1 inhibitor AZD1775, which induces replication failure and...
This $1,288,122 federal Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify multi-level factors associated with HPV vaccine uptake in Kenya and Malawi. The project aims to: (A) Collect primary qualitative and quantitative data, as well as analyze secondary quantitative data, on environmental/policy, health systems, community, and individual-level factors affecting HPV vaccine uptake in Kenya and Malawi....
The National Cancer Institute awarded a $630,506 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Johns Hopkins University for a research project titled "Strategies to Reduce Global Health Disparities in Cervical Cancer." The primary goal is to develop highly effective cancer immunotherapeutic vaccines against cervical cancers associated with HPV16 E6/E7 variants, which are a significant cause of racial and ethnic disparities in HPV16-related cancer outcomes globally. The...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $1,641,683 in funding to The Trustees of the University of Pennsylvania to conduct research focused on understanding the mechanisms by which human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCC) become resistant to current radiation and cisplatin therapies. The goal of the research is to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $216,736 to Northwestern University to conduct research on the role of DNA-PKcs in regulating R-loops during human papillomavirus (HPV) replication. The research aims to uncover how DNA-PKcs activation is necessary to maintain R-loop homeostasis within HPV-positive cells, as preliminary data suggests that...
The National Cancer Institute awarded Ampedrna Biosciences LLC a $398,823 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop a highly immunogenic mini-circular RNA (mRNA) vaccine targeting human papillomavirus (HPV) E6 and E7 proteins for HPV-related cancer immunotherapy. The key goals are to: Demonstrate that a multivalent HPV mRNA vaccine can elicit robust and durable T cell responses that enhance efficacy when combined with immune checkpoint inhibitors for treating HPV-related...